384 related articles for article (PubMed ID: 12867108)
1. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial.
Houghton J; George WD; Cuzick J; Duggan C; Fentiman IS; Spittle M; ; ;
Lancet; 2003 Jul; 362(9378):95-102. PubMed ID: 12867108
[TBL] [Abstract][Full Text] [Related]
2. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial.
Cuzick J; Sestak I; Pinder SE; Ellis IO; Forsyth S; Bundred NJ; Forbes JF; Bishop H; Fentiman IS; George WD
Lancet Oncol; 2011 Jan; 12(1):21-9. PubMed ID: 21145284
[TBL] [Abstract][Full Text] [Related]
3. Management and 5-year outcomes in 9938 women with screen-detected ductal carcinoma in situ: the UK Sloane Project.
Thompson AM; Clements K; Cheung S; Pinder SE; Lawrence G; Sawyer E; Kearins O; Ball GR; Tomlinson I; Hanby A; Thomas JSJ; Maxwell AJ; Wallis MG; Dodwell DJ;
Eur J Cancer; 2018 Sep; 101():210-219. PubMed ID: 30092498
[TBL] [Abstract][Full Text] [Related]
4. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Margolese RG; Cecchini RS; Julian TB; Ganz PA; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
Lancet; 2016 Feb; 387(10021):849-56. PubMed ID: 26686957
[TBL] [Abstract][Full Text] [Related]
5. The consequence of undertreatment of patients treated with breast conserving therapy for ductal carcinoma in-situ.
Lee DY; Lewis JL; Wexelman BA; Freedman BC; Ross RE; Tartter PI
Am J Surg; 2013 Nov; 206(5):790-7. PubMed ID: 23866765
[TBL] [Abstract][Full Text] [Related]
6. Declining recurrence among ductal carcinoma in situ patients treated with breast-conserving surgery in the community setting.
Habel LA; Achacoso NS; Haque R; Nekhlyudov L; Fletcher SW; Schnitt SJ; Collins LC; Geiger AM; Puligandla B; Acton L; Quesenberry CP
Breast Cancer Res; 2009; 11(6):R85. PubMed ID: 19922614
[TBL] [Abstract][Full Text] [Related]
7. Breast-conserving treatment for ductal carcinoma in situ: Impact of boost and tamoxifen on local recurrences.
Cutuli B; Wiezzane N; Palumbo I; Barbieri P; Guenzi M; Huscher A; Borghesi S; Delva C; Iannone T; Vianello E; Rosetto ME; Aristei C
Cancer Radiother; 2016 Jun; 20(4):292-8. PubMed ID: 27344537
[TBL] [Abstract][Full Text] [Related]
8. A review of the management of ductal carcinoma in situ following breast conserving surgery.
Boxer MM; Delaney GP; Chua BH
Breast; 2013 Dec; 22(6):1019-25. PubMed ID: 24070852
[TBL] [Abstract][Full Text] [Related]
9. Postoperative Tamoxifen for ductal carcinoma in situ: Cochrane systematic review and meta-analysis.
Staley H; McCallum I; Bruce J
Breast; 2014 Oct; 23(5):546-51. PubMed ID: 25023044
[TBL] [Abstract][Full Text] [Related]
10. Postoperative tamoxifen for ductal carcinoma in situ.
Staley H; McCallum I; Bruce J
Cochrane Database Syst Rev; 2012 Oct; 10():CD007847. PubMed ID: 23076938
[TBL] [Abstract][Full Text] [Related]
11. Management of ductal carcinoma in situ.
Hwang ES; Esserman LJ
Surg Clin North Am; 1999 Oct; 79(5):1007-30, viii. PubMed ID: 10572548
[TBL] [Abstract][Full Text] [Related]
12. Omitting radiotherapy in women ≥ 65 years with low-risk early breast cancer after breast-conserving surgery and adjuvant endocrine therapy is safe.
Wickberg Å; Liljegren G; Killander F; Lindman H; Bjöhle J; Carlberg M; Blomqvist C; Ahlgren J; Villman K
Eur J Surg Oncol; 2018 Jul; 44(7):951-956. PubMed ID: 29709338
[TBL] [Abstract][Full Text] [Related]
13. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial.
Overgaard M; Jensen MB; Overgaard J; Hansen PS; Rose C; Andersson M; Kamby C; Kjaer M; Gadeberg CC; Rasmussen BB; Blichert-Toft M; Mouridsen HT
Lancet; 1999 May; 353(9165):1641-8. PubMed ID: 10335782
[TBL] [Abstract][Full Text] [Related]
14. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial.
Fisher B; Dignam J; Wolmark N; Wickerham DL; Fisher ER; Mamounas E; Smith R; Begovic M; Dimitrov NV; Margolese RG; Kardinal CG; Kavanah MT; Fehrenbacher L; Oishi RH
Lancet; 1999 Jun; 353(9169):1993-2000. PubMed ID: 10376613
[TBL] [Abstract][Full Text] [Related]
15. Treatment of ductal carcinoma in situ: an uncertain harm-benefit balance.
Prescrire Int; 2013 Dec; 22(144):298-303. PubMed ID: 24600734
[TBL] [Abstract][Full Text] [Related]
16. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ.
Tjalma WA
Lancet; 2003 Oct; 362(9390):1156-7. PubMed ID: 14550711
[No Abstract] [Full Text] [Related]
17. The management of ductal carcinoma in situ (DCIS). The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Canadian Association of Radiation Oncologists.
CMAJ; 1998 Feb; 158 Suppl 3():S27-34. PubMed ID: 9484276
[TBL] [Abstract][Full Text] [Related]
18. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ.
Baroni G; Pedotti A; Orecchia R
Lancet; 2003 Oct; 362(9390):1155; author reply 1155-6. PubMed ID: 14550709
[No Abstract] [Full Text] [Related]
19. [Breast ductal carcinoma in situ with microinvasion: pathological review and clinical implications].
Modesto A; Gandy C; Mery E; Filleron T; Massabeau C; Izar F; Charitansky H; Roché H; de Lafontan B
Cancer Radiother; 2014 Mar; 18(2):107-10. PubMed ID: 24637020
[TBL] [Abstract][Full Text] [Related]
20. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ.
Zammit C; Yelland A; Deutsch G
Lancet; 2003 Oct; 362(9390):1154; author reply 1155-6. PubMed ID: 14550708
[No Abstract] [Full Text] [Related]
[Next] [New Search]
